Pfizer Inc. (PFE) Stock Rating Reaffirmed by Sanford C. Bernstein
Pfizer Inc. (NYSE:PFE)‘s stock had its “outperform” rating reissued by stock analysts at Sanford C. Bernstein in a research report issued on Monday.
A number of other research analysts have also recently commented on PFE. Jefferies Group dropped their target price on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating for the company in a report on Tuesday, September 13th. Argus reissued a “buy” rating and issued a $39.00 target price on shares of Pfizer in a report on Sunday, August 28th. Bank of America Corp. set a $40.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 23rd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $40.00 target price on shares of Pfizer in a report on Tuesday, August 23rd. Ten research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Pfizer has a consensus rating of “Buy” and a consensus price target of $38.78.
Pfizer (NYSE:PFE) opened at 33.83 on Monday. Pfizer has a 1-year low of $28.25 and a 1-year high of $37.39. The company has a market cap of $205.20 billion, a price-to-earnings ratio of 29.99 and a beta of 0.87. The company’s 50-day moving average is $34.60 and its 200 day moving average is $34.02.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same quarter in the prior year, the business posted $0.56 earnings per share. Pfizer’s revenue was up 10.9% compared to the same quarter last year. On average, equities analysts predict that Pfizer will post $2.46 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 3.55%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.
A number of hedge funds have recently bought and sold shares of the stock. Nelson Roberts Investment Advisors LLC increased its position in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares in the last quarter. Stelac Advisory Services LLC purchased a new position in Pfizer during the second quarter worth about $110,000. Tuttle Tactical Management LLC purchased a new position in Pfizer during the second quarter worth about $117,000. Delphi Private Advisors LLC increased its position in Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares in the last quarter. Finally, Commonwealth Financial Services LLC increased its position in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares in the last quarter. 69.65% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.